摘要
目的 研究瑞宁得（ａｎａｓｔｒｏｚｏｌｅ） 治疗绝经后妇女晚期乳腺癌的临床疗效和不良反应。方法 采用多中心开放非随机自身对照方法。６１ 例绝经妇女晚期乳腺癌患者口服瑞宁得每日１ 次，每次１ ｍｇ，连服４～６ 周。疗前２ 周内及治疗４ 周后的３ 天内检测血中雌二醇（Ｅ２） 水平，同时评价疗效和不良反应。结果 ６０ 例可评价疗效和不良反应。部分缓解（ＰＲ）１３ 例，好转（ＭＲ）２ 例，缓解率２１－７％ ，有效率２５－０％ 。绝经时间长者疗效明显优于绝经时间短者；仅接受过辅助性内分泌治疗的疗效，亦较复发后接受过内分泌治疗的疗效好；ＥＲ 阳性疗效较阴性好。疗后对Ｅ２ 的平均抑制率为５８－３％ 。主要不良反应有恶心、乏力、皮肤潮红，一般较轻，可耐受。结论 瑞宁得对Ｅ２ 的抑制作用和对绝经后晚期乳腺癌疗效肯定，不良反应轻微。
Objective To study the effect and adverse reactions of anastrozole in the treatment of postmenopausal women with advanced breast cancer. Methods A multicenter, open, non randomized and crossover clinical trial on the effect of anastrozole was conducted. Sixty one postmenopausal women with advanced breast cancer were treated by oral anastrozole, 1 mg once every day. Each patient received 4～6 weeks of treatment. Plasma estradiol concentrations were determined 2 weeks before treatment and within 3 days after treatment discontinued. Effect and adverse reaction were evaluated. Results The response rate in 60 evaluable cases treated with anastrozole was 21.7% (CR=0, PR=13, MR=2). The effect was correlated with postmenopausal time, previous endocrine therapy and ER status. Plasma level of estradiol was suppressed by 58.3%. The main adverse reactions, including nausea, fatigue, facial flush, were generally tolerable. Conclusion As an aromatase inhibitor capable of decreasing plasma estradiol level, anastrozole is therapeutically effective for advanced breast cancer in postmenopausal women. Side effects are mild and tolerable.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1999年第5期376-378,共3页
Chinese Journal of Oncology
关键词
乳腺癌
药物疗法
瑞宁得
绝经后
Breast neoplasms/drug therapy Anastrozole/therapeutic use Estradiol/blood Postmenopause
